查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806242

幹細胞治療市場按治療類型、細胞來源、技術、給藥方法、應用、治療領域和最終用戶分類－2025-2030 年全球預測

Stem Cell Therapy Market by Therapy Type, Cell Source, Technology, Mode of Administration, Application, Therapeutic Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年幹細胞治療市值將達44.5億美元，2025年成長至50.8億美元，複合年成長率為14.33%，到2030年將達到99.5億美元。

主要市場統計數據
基準年2024年 44.5億美元
預計2025年 50.8億美元
預測年份 2030 99.5億美元
複合年成長率（%） 14.33%

創新幹細胞療法開啟醫療保健新紀元，徹底改變病患治療效果，並重新定義全球治療模式

幹細胞療法正迅速崛起，成為現代醫學中最具前景的前沿領域之一，為修復受損組織、調節免疫反應以及改善各種慢性和急性疾病患者的預後提供了前所未有的可能性。透過利用這些多功能細胞與生俱來的再生能力，研究人員和臨床醫生正在重新定義神經退化性疾病的治療模式。細胞培養技術、基因編輯、生醫材料和法律規範的不斷進步，正在將幹細胞干預從實驗室的好奇心提升到切實可行的臨床應用。

突破性發現和技術的融合如何推動幹細胞療法開發和應用的根本性變革

近年來，基因編輯、誘導性多功能幹細胞(iPSC) 重編程以及自動化生產平台等突破性技術進步，顯著改變了幹細胞治療的模式。這些進步正在匯聚，加速臨床應用並擴大治療範圍。例如，基於 CRISPR 的基因編輯技術的改進使得能夠精確修復患者來源細胞中的基因缺陷，為罕見遺傳疾病的個人化再生干預打開了大門。

分析近期美國關稅政策對幹細胞治療供應鏈和研究前景的廣泛影響

2025年初美國新關稅的訂定，將對整個幹細胞治療供應鏈和研究生態系統產生一系列波動。關鍵原料、專用試劑和高精度設備的投入成本不斷上漲，其中許多都來自國際採購，這給學術研究機構和商業製造商都帶來了衝擊。因此，採購團隊正在重新談判長期契約，並尋找具有本地製造能力的替代供應商。

透過探索不同的治療類型、細胞來源、技術、遞送方法、應用、治療目標和最終用戶來提取關鍵見解

透過考慮治療類型、細胞來源、技術、給藥途徑、應用領域、治療標靶和最終用戶之間的相互關係，可以更清楚地洞察幹細胞治療市場。利用供體來源細胞的同種異體細胞療法因其可擴展的生產效率而發展勢頭強勁，而自體細胞療法則因其個性化的安全性而持續受到青睞，儘管其個體化處理成本更高。然而，自體幹細胞療法因其個人化的安全性而仍然具有吸引力，儘管其個體化處理成本更高。由於造血和間質平台的成熟，成體幹細胞仍然是治療的主流，而神經前驅細胞在中樞神經系統疾病的應用也正在取得進展。胚胎幹細胞正在開闢一個多功能為關鍵的市場，而羊水和臍帶細胞等周產期細胞則兼具倫理可接受性和強大的分化潛力。

繪製美洲、歐洲、中東和非洲以及亞太地區幹細胞治療市場的關鍵區域動態、成長機會和新興趨勢

區域動態在塑造幹細胞療法開發和商業化軌跡方面發揮著至關重要的作用。在美洲，美國憑藉其強大的資金籌措環境、完善的臨床試驗基礎設施以及兼顧病患安全與快速治療途徑的法律規範，處於領先地位。加拿大透過對轉化研究中心的策略性資助鞏固了其地位，而拉丁美洲國家則開始利用經濟高效的臨床網路和政府支持政策來吸引國際夥伴關係。

檢驗全球領先開發商在不斷發展的幹細胞治療產業格局中的策略定位和創新藍圖

幹細胞治療的競爭格局由在科學創新、監管環境和戰略夥伴關係方面表現卓越的公司決定。主要企業已展現出透過整合專有技術和強大的生產平台，將早期研究推進到關鍵臨床試驗的能力。一些創新公司專注於基因工程同種異體細胞株係以治療罕見遺傳疾病，而另一些則致力於最佳化間質幹細胞結構以用於治療發炎性疾病和組織修復。

加速創新、最佳化營運和加強幹細胞治療合作的可行策略和最佳實踐

產業領導者應優先投資模組化生產系統，以實現快速規模生產並靈活適應多種細胞類型和治療標靶。採用一次性生物反應器和封閉式系統處理，可以幫助企業最大限度地降低交叉污染的風險，並加速各設施之間的技術轉移。同時，與試劑供應商和專業設備供應商建立策略聯盟，可確保優先獲得關鍵投入，並促進合作開發舉措。

我們嚴格的調查方法結合了質性訪談、定量資料分析和專家檢驗，為幹細胞治療提供了可靠的見解。

本研究採用混合方法，整合定性和定量數據，以整體情況幹細胞治療領域。主要研究透過對領先生物製藥公司的高階主管、監管代表、學術研究人員和製造外包專業人員進行深入訪談進行。這些討論有助於深入了解幹細胞治療的發展挑戰、投資重點和應用障礙。

整合關鍵發現，明確未來發展路徑，推動全球幹細胞應用領域下一代治療突破

技術進步、政策轉變和市場動態的交匯，凸顯了幹細胞療法發展的關鍵時刻。基因調控和細胞製造領域的突破正在克服規模化和一致性等歷史性瓶頸。同時，不斷發展的監管政策和策略合作正在降低發展路徑的風險，並創造有利於創新的環境。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴大採用幹細胞衍生的外泌體療法作為無細胞再生藥物的替代品
  • 自體脂肪幹細胞治療骨關節炎疼痛的進展
  • 針對血液疾病的基因編輯幹細胞療法的監管核准途徑
  • 將3D生物列印技術與誘導性多功能幹細胞結合用於器官再生研究
  • 間質幹細胞產品在運動醫學的商業化挑戰與報銷策略
  • 用於脊髓損傷恢復的現成同種異體神經幹細胞治療方法的出現
  • 人工智慧在最佳化幹細胞製造和品管工作流程的應用
  • 擴大誘導性多功能幹細胞治療神經系統疾病的臨床試驗
  • 利用生物材料支架進行創新幹細胞療法，以改善細胞移植和組織再生結果
  • 一種新型照護現場自體細胞治療裝置可以使治療更易於獲得且擴充性

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章 幹細胞治療市場（依治療類型）

  • 順勢療法
  • 自體治療

第9章幹細胞治療市場：細胞來源

  • 成體幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
  • 胚胎幹細胞
  • 誘導性多功能細胞
  • 周產期幹細胞
    • 羊水幹細胞
    • 臍帶幹細胞

第 10 章幹細胞治療市場：依技術

  • 基於生物材料的療法
  • 體外生長
  • 基因編輯技術
  • 支架療法

第11章 幹細胞治療市場（依給藥方式）

  • 關節內
  • 肌肉注射
  • 靜脈

第 12 章幹細胞治療市場：依應用

  • 藥物研發
  • 再生醫學
  • 組織工程

第13章 幹細胞治療市場：依治療領域

  • 心血管疾病
  • 血液學
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腫瘤學

第 14 章 幹細胞治療市場（依最終使用者）

  • 學術研究機構
  • 生物製藥公司
  • 醫院和診所
  • 幹細胞庫

15.美洲幹細胞治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 歐洲、中東和非洲幹細胞治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 17 章：亞太幹細胞治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第18章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • BrainStorm Cell Therapeutics Inc.
    • Merck KGaA
    • Anterogen Co., Ltd.
    • Astellas Pharma Inc.
    • Beike Biotechnology Co., Ltd.
    • Bristol-Myers Squibb Company
    • CellProthera SAS
    • Fate Therapeutics, Inc.
    • Gamida Cell Ltd.
    • Garuda Therapeutics
    • Holostem Terapie Avanzate Srl
    • Jasper Therapeutics, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Juvena Therapeutics Inc.
    • Kangstem Biotech Co., Ltd.
    • Kite Pharma, Inc. by Gilead Sciences, Inc.
    • Lonza Group AG
    • Medeze Group
    • Mesoblast Ltd.
    • Novo Nordisk A/S
    • Plasticell
    • ReNeuron Group PLC
    • SQZ Biotechnologies Company by Stemcell Technologies
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • US Stem Cell Inc
    • Umoja Biopharma
    • Vericel Corporation

第19章 研究人工智慧

第20章 研究統計

第21章 研究聯絡人

第22章 研究報導

第23章 附錄

Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 4.45 billion in 2024 and is projected to grow to USD 5.08 billion in 2025, with a CAGR of 14.33%, reaching USD 9.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.45 billion
Estimated Year [2025] USD 5.08 billion
Forecast Year [2030] USD 9.95 billion
CAGR (%) 14.33%

Pioneering a New Era in Healthcare with Innovative Stem Cell Therapies Revolutionizing Patient Outcomes and Redefining Treatment Paradigms Globally

Stem cell therapy is rapidly emerging as one of the most promising frontiers in modern medicine, offering unprecedented potential to repair damaged tissues, modulate immune responses, and transform patient outcomes across a variety of chronic and acute conditions. By harnessing the innate regenerative capabilities of these pluripotent and multipotent cells, researchers and clinicians are redefining treatment paradigms from neurodegenerative disorders to cardiovascular disease. The convergence of advances in cell culture techniques, gene editing, biomaterials, and regulatory frameworks has elevated stem cell interventions from laboratory curiosities to viable clinical applications.

Against this backdrop, the executive summary provides a concise yet thorough exploration of the forces reshaping the stem cell therapy landscape. It examines groundbreaking technological developments, analyzes the implications of recent policy shifts, and distills critical insights drawn from segmentation and regional dynamics. Emphasis is placed on understanding how emerging cell sources and manufacturing platforms are unlocking new therapeutic avenues, while a spotlight on key stakeholders reveals strategic pathways to leadership.

Drawing on primary interviews with industry experts, secondary literature, and rigorous data validation, this overview equips decision-makers with the knowledge required to navigate complexities and capitalize on opportunities. Whether you are a researcher seeking collaboration, an investor assessing risk, or a corporate strategist charting growth, this executive summary lays the foundation for informed action and sustained innovation.

How Groundbreaking Discoveries and Technological Convergence Are Driving Fundamental Shifts in Stem Cell Therapy Development and Adoption

Recent years have witnessed transformative shifts in the stem cell therapy landscape, driven by breakthroughs in gene editing, induced pluripotent stem cell (iPSC) reprogramming, and automated manufacturing platforms. These innovations are converging to accelerate clinical translation and broaden therapeutic reach. For instance, the refinement of CRISPR-based editing techniques has enabled precise correction of genetic defects in patient-derived cells, opening doors to personalized regenerative interventions for rare inherited disorders.

Parallel advances in scaffold-based delivery systems and biomaterial engineering are enhancing cell viability and targeted engraftment, mitigating historic challenges associated with retention and survival at injury sites. Ex vivo expansion technologies further bolster scalability by allowing the production of high-quality cell populations under controlled conditions, thereby reducing variability and ensuring consistency across batches.

Moreover, public-private partnerships and cross-sector collaborations have fostered shared infrastructure, regulatory guidance, and pooled expertise. These cooperative frameworks are streamlining early-phase clinical trials, facilitating accelerated approval pathways, and de-risking investments. By strategically aligning research institutions, biopharmaceutical firms, and clinical networks, the industry is primed to transition innovative concepts into widespread adoption, marking a pivotal shift from proof-of-concept studies to robust, scalable therapeutic programs.

Analyzing the Broad Ripple Effects of Recent United States Tariff Policies on the Stem Cell Therapy Supply Chain and Research Outlook

The introduction of new tariffs by the United States in early 2025 has triggered a series of reverberations throughout the stem cell therapy supply chain and research ecosystem. Key raw materials, specialized reagents, and high-precision instrumentation-many of which are sourced internationally-have seen input costs rise, affecting both academic laboratories and commercial manufacturers. As a result, procurement teams are renegotiating long-term contracts and exploring alternative suppliers with regional manufacturing capabilities.

In addition to elevated costs, extended customs clearance times have disrupted just-in-time inventory models, compelling facilities to build buffer stocks and adapt warehouse management systems. This shift has inadvertently underscored the value of strategic localization, with some organizations electing to repatriate critical processes closer to end-markets to mitigate tariff exposure.

On the research front, regulatory bodies have shown a willingness to accommodate conditional approvals and rolling submissions in response to supply chain pressures. This flexibility has enabled certain clinical programs to maintain momentum, even as budgetary allocations are rebalanced to absorb incremental import duties. Looking ahead, stakeholders are reevaluating risk management frameworks, prioritizing vertical integration, and forging cross-border alliances to preserve operational continuity and capitalize on evolving policy landscapes.

Unlocking Critical Insights by Examining Diverse Therapy Types, Cell Sources, Technologies, Administration Modes, Applications, Therapeutic Targets, and End Users

Insight into the stem cell therapy market emerges most clearly when one considers the interplay of therapy types, cell sources, technologies, administration routes, application areas, therapeutic focus, and end-user segments. Allogeneic therapies, which leverage donor-derived cells, are gaining momentum thanks to scalable manufacturing efficiencies, whereas autologous approaches continue to appeal for their personalized safety profile despite higher individualized processing costs. From a sourcing perspective, adult stem cells remain a mainstay thanks to established hematopoietic and mesenchymal platforms, while neural precursors are advancing for central nervous system indications. Embryonic stem cells are carving niches where pluripotency is essential, complemented by perinatal populations such as amniotic fluid and umbilical cord cells that combine ethical acceptability with robust differentiation capacity.

On the technological front, biomaterial-enhanced constructs and scaffold systems are optimizing cell delivery and retention. Gene-edited technologies are refining therapeutic specificity by eliminating immunogenic markers and correcting pathogenic variants. Ex vivo expansion solutions are seamlessly integrated with automated bioreactors to deliver consistent cell quality at scale. In parallel, the choice of administration route-ranging from intra-articular injections for musculoskeletal applications to intravenous infusions for systemic disorders-is being tailored to both clinical objectives and patient comfort.

Applications in drug discovery are utilizing stem cell-derived models to predict toxicity and efficacy, while regenerative medicine platforms target tissue restoration across cardiovascular, neurological, and musculoskeletal domains. Tissue engineering collaborations are producing hybrid constructs for organ repair. Across these domains, academic and research institutes fuel basic science discoveries, biopharmaceutical companies shepherd translational programs, hospitals and clinics drive clinical trial enrollment and real-world evidence collection, and specialized stem cell banks underpin both supply reliability and quality assurance.

Mapping Key Regional Dynamics, Growth Opportunities, and Emerging Trends Across the Americas, Europe Middle East Africa, and Asia-Pacific Stem Cell Therapy Markets

Regional dynamics play a decisive role in shaping the trajectory of stem cell therapy development and commercialization. In the Americas, the United States leads with a robust funding environment, established clinical trial infrastructure, and a regulatory framework that balances patient safety with accelerated pathways. Canada is bolstering its position through strategic funding of translational research hubs, while Latin American countries are beginning to attract international partnerships by leveraging cost-effective clinical networks and supportive government incentives.

Within Europe, Middle East, and Africa, Europe's landscape is characterized by harmonized regulatory guidelines and a vibrant community of centers of excellence. Western European nations are driving first-in-human studies, while emerging markets in the Middle East and North Africa are investing in biomanufacturing capacity and public-private innovation clusters. Collaborative frameworks between the European Medicines Agency and regional authorities are laying the foundation for unified compassionate use programs and standardized quality controls.

In the Asia-Pacific arena, nations such as Japan and South Korea have established favorable cell therapy roadmaps, including conditional approvals and reimbursement models that mitigate development risk. China's expansive clinical trial footprint and growing network of contract development and manufacturing organizations present both opportunities and competitive pressures. India, Australia, and Southeast Asian nations are accelerating research through government grants and cross-border research partnerships, creating a diverse ecosystem that spans early-stage discovery to late-stage commercialization.

Examining Strategic Positioning and Innovation Roadmaps of Leading Global Developers in the Evolving Stem Cell Therapy Industry Landscape

The competitive landscape of stem cell therapy is defined by organizations that excel in scientific innovation, regulatory navigation, and strategic partnerships. Leading companies have demonstrated the capacity to advance early-stage research into pivotal trials by integrating proprietary technologies with robust manufacturing platforms. Some innovators are focusing on gene-edited allogeneic cell lines to address rare genetic disorders, while others are optimizing mesenchymal stem cell constructs for inflammatory conditions and tissue repair.

Strategic alliances between biotech firms and large pharmaceutical companies are accelerating late-stage clinical development, leveraging established distribution channels and deep reimbursement expertise. Contract development and manufacturing organizations are stepping into the spotlight by offering end-to-end solutions, from cell banking through fill-and-finish operations, thereby de-risking capital expenditure for small to mid-sized developers.

In parallel, a number of academic spin-off enterprises are carving out niches by translating novel differentiation protocols or biomaterial formulations into early-phase trials. Venture capital and strategic corporate investors continue to back these high-potential ventures, focusing on pipelines that span oncology to neurological diseases. Collectively, these stakeholders are reshaping the sector by aligning scientific ambition with commercial pragmatism, setting new benchmarks for efficacy, safety, and scalability.

Implementable Strategies and Best Practices Designed to Accelerate Innovation, Optimize Operational Frameworks, and Enhance Collaboration in Stem Cell Therapy

Industry leaders should prioritize investment in modular manufacturing systems that allow rapid scale-up and flexible adaptation to multiple cell types and therapeutic targets. By adopting single-use bioreactors and closed-system processing, organizations can minimize cross-contamination risk and accelerate technology transfer across facilities. Concurrently, forging strategic alliances with reagent suppliers and specialized equipment vendors will secure preferential access to critical inputs and foster co-development initiatives.

To navigate evolving regulatory landscapes, companies must implement proactive engagement strategies with health authorities, submitting data packages that emphasize process validation and real-world evidence. Leveraging adaptive trial designs can shorten timelines while preserving rigorous safety and efficacy standards. Building global trial networks and harmonizing clinical protocols will also reduce duplicate efforts and streamline patient recruitment.

Furthermore, embracing digital health solutions-such as remote monitoring, electronic patient-reported outcomes, and blockchain-enabled supply chain tracking-will enhance transparency, patient adherence, and quality control. Finally, cultivating cross-disciplinary talent through targeted training programs and academic collaborations will ensure the workforce remains adept at integrating emerging science with commercial imperatives, laying the groundwork for sustainable growth.

Rigorous Methodological Approach Combining Qualitative Interviews, Quantitative Data Analysis, and Expert Validation to Ensure Robust Stem Cell Therapy Insights

This research is founded upon a mixed-methods approach that integrates qualitative and quantitative data to produce a holistic view of the stem cell therapy sector. Primary research was conducted through in-depth interviews with executives from leading biopharmaceutical firms, regulatory agency representatives, academic investigators, and contract manufacturing experts. These discussions provided nuanced understanding of development challenges, investment priorities, and adoption barriers.

Secondary research encompassed a thorough review of peer-reviewed publications, patent filings, government policy documents, and public company disclosures. Data points were triangulated to verify consistency and identify divergent trends across sources. Proprietary databases tracking clinical trial activities, technology licensing agreements, and capital investment flows were also leveraged to ensure comprehensive coverage.

All quantitative inputs underwent rigorous validation through cross-referencing with expert feedback. Key assumptions were stress-tested under multiple scenarios to assess impact on operational and regulatory variables. The resulting framework ensures that insights are both robust and actionable, offering stakeholders a reliable foundation for strategic decision-making in this rapidly evolving domain.

Synthesizing Critical Discoveries and Identifying Future Pathways to Propel the Next Generation of Therapeutic Breakthroughs in Stem Cell Applications Worldwide

The synthesis of technological advances, policy shifts, and market dynamics underscores a pivotal moment for the maturation of stem cell therapies. Breakthroughs in gene regulation and cell manufacturing are converging to overcome historical bottlenecks in scale and consistency. At the same time, evolving regulatory policies and strategic collaborations are de-risking development pathways and fostering an environment conducive to innovation.

Segmentation insights reveal that no single approach will dominate; rather, a diversified portfolio encompassing allogeneic and autologous products, multiple cell sources, and varied delivery platforms will characterize the next phase of growth. Regional analyses highlight that global market penetration will depend on tailoring strategies to local regulatory, reimbursement, and infrastructure conditions.

Ultimately, success in this arena will hinge on aligning scientific rigor with commercial agility, forging partnerships across the ecosystem, and maintaining an unwavering focus on patient-centered outcomes. By synthesizing these critical discoveries and identifying future pathways, stakeholders are better positioned to usher in the next generation of therapeutic breakthroughs and deliver transformative care to patients around the world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising adoption of exosome-based therapeutics derived from stem cells as cell-free regenerative medicine alternatives
  • 5.2. Advancements in autologous adipose-derived stem cell therapies for osteoarthritis pain management
  • 5.3. Regulatory approval pathways for gene-edited stem cell therapies targeting hematologic disorders
  • 5.4. Integration of 3D bioprinting techniques with induced pluripotent stem cells for organ regeneration research
  • 5.5. Commercialization challenges and reimbursement strategies for mesenchymal stem cell products in sports medicine
  • 5.6. Emergence of off-the-shelf allogeneic neural stem cell treatments for spinal cord injury recovery
  • 5.7. Application of artificial intelligence in optimizing stem cell manufacturing and quality control workflows
  • 5.8. Clinical trial expansions targeting neurological disorders with induced pluripotent stem cell therapies
  • 5.9. Innovations in biomaterial scaffolds improving cell engraftment and tissue regeneration outcomes in stem cell therapy
  • 5.10. Emerging point-of-care autologous cell therapy devices enhancing treatment accessibility and scalability

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Stem Cell Therapy Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Allogeneic Therapy
  • 8.3. Autologous Therapy

9. Stem Cell Therapy Market, by Cell Source

  • 9.1. Introduction
  • 9.2. Adult Stem Cells
    • 9.2.1. Hematopoietic Stem Cells
    • 9.2.2. Mesenchymal Stem Cells
    • 9.2.3. Neural Stem Cells
  • 9.3. Embryonic Stem Cells
  • 9.4. Induced Pluripotent Stem Cells
  • 9.5. Perinatal Stem Cells
    • 9.5.1. Amniotic Fluid Stem Cells
    • 9.5.2. Umbilical Cord Stem Cells

10. Stem Cell Therapy Market, by Technology

  • 10.1. Introduction
  • 10.2. Biomaterial Based Therapy
  • 10.3. Ex Vivo Expansion
  • 10.4. Gene Edited Technologies
  • 10.5. Scaffold Based Therapy

11. Stem Cell Therapy Market, by Mode of Administration

  • 11.1. Introduction
  • 11.2. Intra-articular
  • 11.3. Intramuscular
  • 11.4. Intravenous

12. Stem Cell Therapy Market, by Application

  • 12.1. Introduction
  • 12.2. Drug Discovery & Development
  • 12.3. Regenerative Medicine
  • 12.4. Tissue Engineering

13. Stem Cell Therapy Market, by Therapeutic Areas

  • 13.1. Introduction
  • 13.2. Cardiovascular Diseases
  • 13.3. Hematology
  • 13.4. Musculoskeletal Disorders
  • 13.5. Neurological Disorders
  • 13.6. Oncology

14. Stem Cell Therapy Market, by End User

  • 14.1. Introduction
  • 14.2. Academic & Research Institutes
  • 14.3. Biopharmaceutical Companies
  • 14.4. Hospitals & Clinics
  • 14.5. Stem Cell Banks

15. Americas Stem Cell Therapy Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Stem Cell Therapy Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Stem Cell Therapy Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. BrainStorm Cell Therapeutics Inc.
    • 18.3.2. Merck KGaA
    • 18.3.3. Anterogen Co., Ltd.
    • 18.3.4. Astellas Pharma Inc.
    • 18.3.5. Beike Biotechnology Co., Ltd.
    • 18.3.6. Bristol-Myers Squibb Company
    • 18.3.7. CellProthera SAS
    • 18.3.8. Fate Therapeutics, Inc.
    • 18.3.9. Gamida Cell Ltd.
    • 18.3.10. Garuda Therapeutics
    • 18.3.11. Holostem Terapie Avanzate S.r.l.
    • 18.3.12. Jasper Therapeutics, Inc.
    • 18.3.13. JCR Pharmaceuticals Co., Ltd.
    • 18.3.14. Juvena Therapeutics Inc.
    • 18.3.15. Kangstem Biotech Co., Ltd.
    • 18.3.16. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 18.3.17. Lonza Group AG
    • 18.3.18. Medeze Group
    • 18.3.19. Mesoblast Ltd.
    • 18.3.20. Novo Nordisk A/S
    • 18.3.21. Plasticell
    • 18.3.22. ReNeuron Group PLC
    • 18.3.23. SQZ Biotechnologies Company by Stemcell Technologies
    • 18.3.24. Takara Bio Inc.
    • 18.3.25. Thermo Fisher Scientific Inc.
    • 18.3.26. U.S. Stem Cell Inc
    • 18.3.27. Umoja Biopharma
    • 18.3.28. Vericel Corporation

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. STEM CELL THERAPY MARKET: RESEARCHAI
  • FIGURE 30. STEM CELL THERAPY MARKET: RESEARCHSTATISTICS
  • FIGURE 31. STEM CELL THERAPY MARKET: RESEARCHCONTACTS
  • FIGURE 32. STEM CELL THERAPY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 184. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 258. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 271. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 273. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 289. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 307. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 309. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 312. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 323. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 325. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 331. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 333. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 335. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 337. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED ARAB EMI